For someone living with a tumor around a joint, a smaller tumor is welcome news. But the question behind the scan is often more practical: Will I be able to bend my knee, walk comfortably, or avoid an operation that could leave me with less function?
That distinction is central to the FDA's November 10, 2026 approval of pimicotinib, marketed in the United States as Pimjetmi. It is approved for adults with symptomatic tenosynovial giant cell tumor, or TGCT, when surgical removal may worsen functional limitation or cause severe morbidity. The wording matters. This is a treatment for a particular clinical dilemma, rather than a recommendation that every TGCT should receive a drug. [1]
A tumor can be serious without being metastatic
TGCT is a rare tumor affecting the tissue around joints and tendon sheaths. It is locally aggressive: the burden comes from what it does in and around the affected joint. Pain, stiffness and impaired movement can matter enormously even when a disease does not fit the familiar picture of a spreading cancer. [2]
That changes how treatment success should be judged. The aim is not simply to make an image look better. It is to preserve a person's ability to use the joint, while avoiding harm from both the disease and its treatment.
Surgery remains part of that discussion. Yet removing a tumor and preserving the surrounding structures are not always compatible goals. The new indication recognizes that an operation can be technically possible and still carry an unacceptable functional cost. A drug creates another option in that decision; it does not remove the need to make the decision carefully.
What the randomized trial established
Pimicotinib inhibits the colony-stimulating factor 1 receptor, or CSF1R. This pathway helps sustain the cellular environment involved in TGCT. Its evidence comes from MANEUVER, an international, randomized, double-blind phase 3 trial funded by the drug's developer, Abbisko Therapeutics. [2]
The study assigned 94 adults to pimicotinib or placebo: 63 received the drug and 31 received placebo. Participants had symptomatic disease, with pain or stiffness rated at least 4 out of 10, and received treatment for 24 weeks. The primary endpoint was tumor response at week 25, assessed by an independent committee using RECIST 1.1, a standardized system for measuring tumors. [2]
The FDA reports an objective response rate of 56% with pimicotinib, compared with 3.2% with placebo. The respective 95% confidence intervals were 42–68% and 0.1–17%. [1] An objective response means the tumor met defined imaging criteria for shrinkage or disappearance. It does not mean that 56% of patients were cured or that all of them no longer needed surgery.
The large difference supports a real antitumor effect in this selected population. The trial investigators also reported improvements in functional limitations and symptom burden. [2] Those outcomes are especially relevant here: movement and discomfort are not secondary concerns in a disease centered on a joint.
Still, a trial-level improvement cannot promise the same experience to every patient. A reduction in tumor size may translate differently depending on which joint is involved and how much impairment is already present. That is a clinical interpretation, not a separately proven result of this trial.
The missing comparison is a treatment strategy
MANEUVER compared a drug with placebo over 24 weeks. It did not randomly assign patients to a long-term strategy of medication versus surgery and count how many avoided a disabling operation.
That leaves an important gap between the measured endpoint and one of the most compelling reasons to consider treatment. If a tumor shrinks, does surgery become less extensive? Can surgery be postponed safely? Can some patients avoid it altogether, and for how long? The primary response result alone cannot answer those questions.
Patients completing the blinded period could enter an open-label phase, including crossover from placebo to pimicotinib. [2] Longer follow-up can reveal durability and additional safety information, but crossover means later results do not preserve the same randomized comparison.
For this reason, “the drug shrinks tumors” and “the drug helps patients avoid harmful surgery” should remain distinct claims. The first has strong randomized evidence. The second requires more direct evidence about subsequent operations, joint function and sustained benefit.
No observed liver injury is not no liver risk
Safety also needs more than one sentence. In the published trial, 8 of 63 treated patients had grade 3 or 4 elevations in creatine phosphokinase, a laboratory marker. Five required dose reductions and 1 discontinued treatment. The paper reported no cholestatic hepatotoxicity or drug-induced liver injury during the reported study period. [2]
That observation is reassuring within its limits. It is not proof that the drug cannot injure the liver. The FDA approval information includes a hepatotoxicity warning, along with warnings concerning embryo-fetal toxicity and increased serum creatinine without an effect on renal function. [1] A small trial can establish a useful treatment effect while remaining unable to exclude uncommon harms.
China approved the same drug first
For readers following Chinese medicine development, the timeline is also important. Pimicotinib hydrochloride capsules were approved in China on December 16, 2025, under the brand name 贝捷迈. The Chinese indication likewise covers symptomatic adults whose surgery could cause functional limitation or serious complications. The core treatment setting is therefore similar; the American approval should not be presented as a new expansion beyond China's eligible population. [3–5]
The decision after the headline
The useful question is not whether tumor shrinkage matters. It does. The harder question is how much additional value it creates for a particular person, compared with the available alternatives and the burden of continued treatment.
Evidence that patients retain better joint function, undergo fewer damaging procedures and sustain benefit over time would strengthen that judgment. Evidence that responses depend on prolonged treatment, or that uncommon toxicity changes the balance, could narrow it. Pimicotinib offers a meaningful new option. The next task is to understand when that option changes a patient's life, not only the dimensions of a tumor.
Sources and data note
- FDA, November 10, 2026. Approval announcement, indication, response rates and warnings:
- Xu H et al. MANEUVER. The Lancet. Published online March 5, 2026; journal issue March 14, 2026. DOI: 10.1016/S0140-6736(25)02602-9. Trial: NCT05804045.
https://doi.org/10.1016/S0140-6736(25)02602-9 https://pubmed.ncbi.nlm.nih.gov/41796601/ https://clinicaltrials.gov/study/NCT05804045
- NMPA announcement republished by the China Food and Drug Network, December 22, 2025. Approved Chinese product name, brand and indication:
https://m.cnpharm.com/c/2025-12-22/1087245.shtml
- Beijing Municipal Health Commission / Beijing Jishuitan Hospital, March 30, 2026. Confirms the December 16, 2025 Chinese approval date:
https://wjw.beijing.gov.cn/xwzx_20031/jcdt/202603/t20260330_4569579.html
- Merck 2025 Annual Report, Healthcare research and development. Approval date and indication in the footnote:
Data note: The Lancet paper reports 34/63 responses (54%) versus 1/31 (3.2%), an absolute difference of 51 percentage points (95% CI 33–63). This was the global intention-to-treat population: 45 participants were enrolled in China and 49 outside China. The FDA announcement reports 56% versus 3.2%. The reason for that numerical difference has not been verified; it must not be described as a China-versus-global subgroup difference. The main text uses the FDA's figures for the new US approval.